Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
Price : $35 *
At a glance
- Drugs Eculizumab (Primary)
- Indications Delayed graft function
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 Feb 2018 Status changed from active, no longer recruiting to discontinued.
- 11 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.